FTC Med Spa Enforcement Patterns 2024-2026: The Specific Claim Categories Drawing Attention

Med spas are one of the fastest-growing healthcare practice categories, and the regulatory environment around aesthetic marketing has tightened significantly. The FTC’s 2023 Endorsement Guides update, the Health Products Compliance Guidance, state medical board oversight, and state AG actions together define the claim categories drawing regulatory attention. This post covers those patterns and what practices should adjust.

Pattern 1: Typical-experience disclosure gaps

Before/after imagery and patient testimonials without proper typical-experience disclosure are the single most-common FTC enforcement pattern in med spas. “Results may vary” is not sufficient disclosure under the 2023 Endorsement Guides update - typical actual outcomes must be disclosed.

What regulators focus on: most med spa before/after content pairs peak-outcome imagery with minimal disclosure, creating the impression that peak outcomes are typical. This is a core focus of the FTC Health Products Compliance Guidance and the 2023 Endorsement Guides update. See before/after photos compliance for the specific framing requirements.

Pattern 2: Material-connection gaps in influencer content

Influencer partnerships without FTC-compliant disclosure of paid relationships are a persistent pattern. The 2023 Endorsement Guides update tightened the clear-and-conspicuous standard, and enforcement has followed.

Specific issues: #ad buried in long caption blocks, disclosure in bio link rather than in the post, disclosure in platform-specific paid partnership tools that don’t make the paid status visually prominent, and free-treatment relationships treated as non-paid.

Pattern 3: Aggressive package pricing marketing

Package pricing advertised at introductory rates without adequate disclosure of actual-total pricing (including add-ons, anesthesia, follow-up, recommended treatment series) has been a growing state AG focus. See state AG med spa package pricing enforcement for documented examples.

The pattern: “$X for CoolSculpting cycle” where the actual treatment plan involves multiple cycles at non-promotional rates, or “$Y for lip filler” where the typical treatment requires more filler than the promotional amount.

Pattern 4: FDA-approved vs FDA-cleared misuse

Device marketing conflating “FDA-approved” with “FDA-cleared” is one of the most consistently-cited patterns in aesthetic marketing. Most aesthetic devices are 510(k) cleared; using “FDA-approved” for these is factually wrong. The FDA’s “Is It Really FDA Approved?” explains the distinction, and FDA-approved vs FDA-cleared for aesthetic devices covers the med spa-specific context.

Pattern 5: Off-label indication promotion

Marketing neuromodulators or fillers for specific off-label indications - jawline slimming, non-surgical rhinoplasty, specific body-contouring applications - is a sustained enforcement pattern. Clinical off-label use may be appropriate; public marketing of off-label indications is not.

Pattern 6: Guarantee and superlative claims

“Guaranteed results,” “best in [city],” “most experienced” without substantiation are common in med spa marketing and consistently cited in enforcement.

Pattern 7: Nurse injector independence language

Coordinated enforcement between state medical boards and FTC on marketing that implies nurse-injector independence when supervision is required. This is a state-medical-board-plus- FTC pattern that creates simultaneous exposure.

Pattern 8: Safety absolutes

“No side effects,” “completely safe,” “painless” - absolute safety claims in aesthetic marketing. These conflict with documented side effect profiles of every injectable, laser, and RF device.

Pattern 9: Celebrity and influencer stock content

Using celebrity imagery or stock content to imply celebrity endorsement when none exists. The 2023 Endorsement Guides specifically address this pattern as deceptive.

Pattern 10: AI-generated testimonials and imagery

An emerging pattern: AI-generated patient testimonials or AI-modified before/after imagery presented as real. The 2023 Guides explicitly flag this as deceptive, and enforcement is expected to develop in 2026.

What med spa practices should adjust

1. Audit every before/after for typical-experience framing.Replace “results may vary” with actual typical-outcome language.
2. Review every influencer partnership for disclosure adequacy. Clear-and-conspicuous in the post itself, not in bio or description.
3. Restructure package pricing marketing.Clear disclosure of what’s included and typical total-treatment cost.
4. Correct FDA-approved vs FDA-cleared language.One afternoon of site audit closes this specific pattern.
5. Review off-label indication marketing.Generic treatment-category marketing vs specific off-label-indication marketing.
6. Remove guarantee language. Outcome guarantees in aesthetic practice create both FTC and private-action exposure.
7. Add supervision disclosure where required.State-specific supervision language for nurse injectors and non-physician providers.
8. Replace safety absolutes.“Most patients tolerate well” with specific common side effects.
9. Verify all imagery is real patients. No stock content presented as patients, no AI-generated patients.
10. Document the compliance program.Pre-publish review, trained staff, audit schedule.

Outlook for 2026

The FTC’s 2023 Endorsement Guides and the Health Products Compliance Guidance have set clear expectations for aesthetic marketing. State AGs and medical boards increasingly coordinate on consumer-protection actions involving med spas. The Stem Cell Institute of America enforcement action illustrates how seriously courts and regulators treat aggressive wellness and regenerative marketing claims in the adjacent regen-medicine space.

Practices that invest in compliance infrastructure enter this environment in a defensible posture. Those that treat compliance as optional face multi-vector exposure across FTC guidelines, state board rules, and AG consumer-protection authority. See med spa marketing compliance risk for a full risk overview.